Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07728097 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

Name: A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS — clinical trial record (NCT07728097)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EpiGOAL

StatusNot Yet Recruiting

PhasePhase 4

SponsorJazz Pharmaceuticals

Started2026-11-18

View on ClinicalTrials.gov ↗

Amendment history

2026-08-27

2 amendments v1-v2

2 re-verifications since 2026-08-19, no change to tracked fields

2026-07-24

Original filing

Jazz Pharmaceuticals

34 trials monitored

See 1 trial at risk

Epilepsy

723 trials monitored

See 41 trials at risk

This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.

Trial Details

NCT Number	NCT07728097
Lead Sponsor	Jazz Pharmaceuticals Collaborators: Jazz Pharmaceuticals Research UK Limited
Conditions	Lennox-Gastaut Syndrome
Enrollment	40 participants
Start Date	2026-11-18
Primary Completion	2028-12-28 (estimated)
Study Completion	2028-12-28 (estimated)
Updated on ClinicalTrials.gov	2026-09-24